Skip to main content Skip to main navigation menu Skip to site footer
Reumatismo - The Italian Journal of Rheumatology

Editor-in-Chief: M.A. Cimmino, Genova, Italy | eISSN 2240-2683

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current Issue
  • Early Access
  • Archives
  • Special Issues
    • Overview
  • Register
  • Login
  • Search
  • Contacts
  • News
1.0
Impact Factor 2024
1.7
CiteScore 2024
1.0
Impact Factor 2024
1.7
CiteScore 2024
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • PO:01:004 | Real-world retention of IL-17 inhibitors in psoriatic arthritis: impact of prior IL-17 exposure across multiple treatment lines in the “BIRRA” multicentre cohort Valentino Paci1, Alarico Ariani2, Eleonora Celletti3, Alberto Lo Gullo4, Camilla Mazzanti5, Valeria Nucera6, Natalia Mansueto7, Rosalba Caccavale8, Patrizia Del Medico9, Antonella Farina10, Palma Scolieri11, Cecilia Giampietro12, Olga Addimanda13, Riccardo Bixio14, Maddalena Larosa15, Viviana Ravagnani16, Federica Lumetti17, Aldo Biagio Molica Colella17, Elena Bravi17, Rosetta Vitetta17, Bernd Raffeiner17, Gilda Sandri18, Rosario Foti19, Simone Parisi20, Michele Maria Luchetti Gentiloni1, Gianluca Moroncini1. | 1Clinical Medicine, Department of Clinical and Molecular Sciences, Marche Polytechnic University, AOU delle Marche, Ancona, Italy; 2Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy; 3Rheumatology Unit, Clinica Medica Institute, Ospedale SS. Annunziata di Chieti, G.d'Annunzio University of Chieti, Chieti, Italy; 4Rheumatology Unit, ARNAS Garibaldi di Catania, Catania, Italy; 5Center for the Diagnosis and Therapy of Autoimmune Rheumagological Diseases, Ospedale Santa Rosa, ASL Viterbo Viterbo Italy; 6Rheumatology Outpatient Unit, ASL Novara, Novara, Italy; 7Ambulatori di Reumatologia ASL1 Liguria, Imperia Hospitall Imperia Italy; 8Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, Roma, Italy; 9Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy; 10Internal Medicine Unit, Rheumatology outpatient clinic, Ospedale A. Murri di Fermo, Fermo, Italy; 11Department of Medical Specialties, Nuovo Regina Margherita Hospital, Rome, Roma, Italy; 12Rheumatology Outpatient Clinic, Azienda ULSS 6 Euganea, Padova, Padova, Italy; 13Rheumatology Unit, Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- AOU di Bologna, Bologna, Italy; 14Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; 15Division of Rheumatology - Medical Specialties Department, Ospedale La Colletta-Azienda Sanitaria Locale 3, Genova, Italy; 16Rheumatology Unit, Santa Chiara Hospital APSS Trento Italy; 17BIRRA - BIologic Retention Rate in chronic Arthritis - study group, Parma, Italy; 18Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; 19Rheumatology Unit, Policlinico San Marco Hospital, Catania, Italy; 20Rheumatology Department, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2001
    203
  • PO:03:036 | Psoriatic arthritis: does pre-existing treatment with cs/bDMARDs for psoriasis influence the characteristics and outcomes of joint disease? Ilenia Marchesini1, Alberto Floris1, Cristina Mugheddu2, Laura Li Volsi1, Maria Teresa Paladino1, Roberta Origa1, Jessica Sorgia1, Mattia Congia1, Elisabetta Chessa1, Matteo Piga1, Caterina Ferreli2, Laura Atzori2, Alberto Cauli1 | 1Unità di Reumatologia, AOU e Università di Cagliari-Monserrato; 2Unità di Dermatologia, AOU e Università di Cagliari, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2127
    171
  • PO:04:046 | Achieving Early Clinical Response was Associated with Cumulative Benefits on Disease Impact up to 2 Years in Patients with Active Psoriatic Arthritis Treated with Bimekizumab William Tillett1|2, Joseph F Merola3, Iain B Mcinnes4, Kenneth B Gordon5, Richard B Warren6, Patrick Healy7, Jérémy Lambert8, Heather Edens9, Barbara Ink10, Paola Volpe11, Laure Gossec12 | 1Royal National Hospital of Rheumatic Diseases Bath, United Kingdom; 2Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath Bath, United Kingdom; 3Department of Dermatology and Department of Medicine, Division of Rheumatology, Utah Southwestern Medical Center Dallas, USA; 4College of Medical Veterinary and Life Sciences, University of Glasgow Glasgow, United Kingdom; 5Department of Dermatology, Medical College of Wisconsin Milwaukee, USA; 6Northern Care Alliance, NHS Foundation Trust and Manchester Academic Health Science Centre, University of Manchester Manchester, United Kingdom; 7UCB Morrisville, USA; 8UCB Colombes, France; 9UCB Smyrna, USA; 10UCB Slough, United Kingdom; 11UOC Reumatologia, P.O. Spirito Santo Pescara, Italy; 12Sorbonne Universite and Pitie-Salpetriere Hospital Paris, France

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2295
    29
  • Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

    G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio
    08-05-2023
    https://doi.org/10.4081/reumatismo.2023.1559
    2099
    PDF: 1119
  • PO:03:034 | Inhibition of Radiographic Progression with Bimekizumab Treatment Observed in bDMARD-Naïve Patients with Active Psoriatic Arthritis at 2 Years: Results from a Phase 3 Study and its Open-Label Extension Laura C Coates1, M Elaine Husni2, Mitsumasa Kishimoto3, Proton Rahman4, Philipp Sewerin5, Enrique R Soriano6, Barbara Ink7, Rajan Bajracharya7, Jason Coarse8, Philip J Mease9, Emanuela Mazzola10, Peter Nash11 | 1NDORMS, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust Oxford, United Kingdom; 2Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Cleveland, USA; 3Department of Nephrology and Rheumatology, Kyorin University School of Medicine Tokyo, Japan; 4Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Memorial University of Newfoundland St. Johns, Canada; 5Rheumazentrum Ruhrgebiet, University Hospital of the Ruhr University Bochum Herne Germany; 6Hospital Italiano de Buenos Aires and University Institute Hospital Italiano de Buenos Aires Buenos Aires, Argentina; 7UCB Slough, United Kingdom; 8UCB Morrisville, USA; 9Department of Rheumatology, Providence-Swedish Medical Center and University of Washington Seattle, USA; 10UCB Milan, Italy; 11School of Medicine, Griffith University, Brisbane, Australia

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2290
    45
  • PO:07:095 | Clinical impact of therapeutic modification following changes in AIFA reimbursement criteria for JAK inhibitors in patients with RA in remission/low disease activity: analysis of the multicenter JAK-SWAP RER study in Emilia-Romagna Marta Raschella1, Giulia Furia1, Martina Di Nunzio1, Francesco Luca Renzullo2, Francesco Girelli2, Federica Pignatti3, Francesco Ursini3, Licia Vultaggio4, Pierluigi Cataleta4, Elena Bravi5, Eugenio Arrigoni5, Francesca Bergossi6, Enrica Vandelli7, Massimo Reta6|7, Viola Magnani8, Andreina Manfredi8|9, Giuseppe Germanò8, Alessandra Bortoluzzi1, Marcello Govoni1, Ettore Silvagni1 | 1Unità Operativa Complessa di Reumatologia, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara e Azienda Ferrara; 2UOS Reumatologia, Ospedale GB Morgagni, Forlì; 3UOC Reumatologia, Istituto ortopedico Rizzoli, Bologna; 4UO Reumatologia, AUSL Romagna Ospedale di Ravenna; 5UO Reumatologia, Azienda USL di Piacenza; 6Reumatologia Osp. Maggiore, Bologna; 7UO Medicina Interna ad Indirizzo Reumatologico Interaziendale SC AUSL Bologna, IRCCS Policlinico di SantOrsola, Bologna; 8U.O Reumatologia, Santa Maria Nuova di Reggio Emilia; 9Università degli studi di Modena e Reggio Emilia, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2135
    156
  • PO:04:061 | Higher prevalence of baseline comorbidities in patients developing difficult to treat psoriatic arthritis Mario Ferraioli1, Michelina Turri1, Eneida Çela1, Mauro Fatica1, Paola Conigliaro1, Elisabetta Greco1, Alberto Bergamini1, Maria Sole Chimenti1. | 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome, Tor Vergata, Rome, Italy.

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2011
    134
  • Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

    M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali
    17-07-2023
    https://doi.org/10.4081/reumatismo.2023.1544
    1412
    PDF: 767
  • PO:08:119 | Infusional Advantage: Rituximab’s Role in Enhancing Adherence in Multimorbid Rheumatoid Arthritis Marco Capodiferro1, Daniele Domanico1, Angelica Napoletano1, Giulia Righetti2, Patrizia Suppressa2, Vincenzo Venerito1, Giuseppe Lopalco1, Florenzo Iannone1, Fabio Cacciapaglia1|2 | 1Rheumatology Unit, Department of Precision and Regenerative Medicine and Jonian Area DiMePRe-J University of Bari, Italy; 2Department of Medicine and Surgery, Miulli General Hospital Acquaviva delle Fonti - LUM University Casamassima Bari Acquaviva delle Fonti, Bari, Italy

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2307
    14
  • PO:01:006 | Increased risk of cancer recurrence or mortality associated with DMARDs? Laura Scagnellato1, Giacomo Cozzi1, Mariagrazia Lorenzin1, Mariangela Salvato1, Alessandro Giollo1, Bernd Raffeiner1, Antonia Calligaro1, Teresa Del Ross1, Sara Bindoli1, Margherita Zen1, Paolo Sfriso1, Andrea Doria1, Roberta Ramonda1. | 1UOC Reumatologia, Dipartimento di Medicina dei Sistemi DIMED, Ospedale Università di Padova, Padova, Italy.

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2003
    163
  • PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta1, Andrew Östör2|8, Eugen Feist3, Prodromos Sidiropoulos4, Jérôme Avouac5, Martin Rebella6|7, Rajaie Namas9, Erin Mcdearmon Blondell10, Ivan Lagunes10, Tianming Gao10, Tim Shaw10, Suzan Attar11 | 1AbbVie Srl Roma, Italy; 2Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; 3Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; 4Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; 5Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; 6Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; 7Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; 8Australian National University, Camberra, Australia; 9Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; 10AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; 11King Abdulaziz University, Jeddah, Saudi Arabia

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2306
    22
  • PO:08:113 | Shaping rheumatoid arthritis treatment: clinical and demographic drivers of tsDMARDs versus bDMARDs prescription post-EMA pronouncement on JAK inhibitors - insights from the AMBI-RA study Riccardo Bertola1, Beatrice Maranini1, Carlo Garaffoni1, Maria Pozzuto1, Anna Laura Riva Cambrino1, Alessandro Spinelli1, Letizia Mamprin1, Federico Agostini1, Martina Di Nunzio1, Marcello Govoni1, Alessandra Bortoluzzi1, Ettore Silvagni1 | 1Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2139
    164
  • PO:06:081 | Safety of JAK inhibitors compared to non-TNF-targeted biologic therapies in rheumatoid arthritis patients who are inadequate responders to TNF inhibitors Lorenzo Di Luozzo1, Alessandro Giollo1, Mariangela Salvato1, Francesca Frizzera1, Kiren Khalid1, Margherita Zen1, Andrea Doria1 | 1Azienda ospedaliera universitaria di Padova, unità di Reumatologia, Padova, Italy

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2298
    39
  • PO:07:103 | Tocilizumab use in patients with rheumatoid arthritis and malignancy: a monocentric experience Vittorio Dibenedetto1|2|3, Nicola Farina1|2, Nicola Boffini1|2, Alessandro Tomelleri1|2, Adriana Cariddi1|2, Elena Baldissera1|2, Marco Matucci-Cerinic1|2|3, Lorenzo Dagna1|2|3. | 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano, Italy; 2Inflammation, Fibrosis and Ageing Intitiative INFLAGE, IRCCS San Raffaele Hospital, Milano, Italy; 3Vita-Salute San Raffaele University, Milano, Italy.

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2021
    135
  • PO:02:024 | Development of anti-drug antibodies in patients with peripheral and/or axial spondyloarthritis treated with infliximab or adalimumab: a monocentric cross-sectional study Gabriele Amati1, Gilda Sandri1|2, Alessandra Melegari3, Benedetta Bongiovanni1|2, Giovanni Ciancio2, Martina Orlandi1|2, Ottavio Secchi1, Dilia Giuggioli1|2 | 1Struttura complessa di Reumatologia, Azienda Ospedaliero-Universitaria Policlinico di Modena; 2Cattedra di Reumatologia, Università degli studi di Modena e Reggio Emilia; 3Dipartimento di medicina di laboratorio, Ospedale di Baggiovara, AUSL di Modena, Italy

    Società Italiana di Reumatologia
    25-11-2025
    https://doi.org/10.4081/reumatismo.2025.2126
    153
  • PO:03:044 | Impact of Inflammatory Bowel Disease on Clinical Phenotype and Treatment Response in Patients with Psoriatic Arthritis Maria Morrone1, Maria Giannotta1, Vincenzo Venerito1, Greta Giulia Dipietrangelo1, Stefano Stano1, Florenzo Iannone1, Giuseppe Lopalco1 | 1Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J University of Bari, Bari, Italy

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2294
    28
  • PO:35:222 | Distinctive Features of Localized Vasculitis of the Gastrointestinal Tract Compared to Takayasu Arteritis: Insights from a Multicenter Cohort Study Vittorio Dibenedetto1|2|3, Alessandro Tomelleri1|2, Corrado Campochiaro1|2, Elena Baldissera1|2, Luca Moroni1|2, Padoan Roberto4, Marco Matucci-Cerinic1|2|3, Lorenzo Dagna1|2|3 | 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases UNIRAR, IRCCS San Raffaele Hospital Milan, Italy; 2Inflammation, Fibrosis and Ageing Intitiative INFLAGE, IRCCS San Raffaele Hospital Milan, Italy; 3Vita-Salute San Raffaele University, Milan, Italy Milan, Italy; 4University Hospital of Padova, Department of Internal Medicine and Rheumatology Padova, Italy

    Società Italiana di Reumatologia
    18-03-2026
    https://doi.org/10.4081/reumatismo.2025.2382
    14
1 - 17 of 17 items
Make a Submission

authors

FOR AUTHORS
  • ARTICLE PROCESSING CHARGE
  • Guide for Authors
  • Benefits for Authors
  • How to write a scientific paper
  • How to write a Review article

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to review
  • Thanks to Reviewers

Categories

    • Abstract Book
    • Oral Communications - Day 1
    • Posters - Day 1
    • Oral Communications - Day 2
    • Posters - Day 2
    • Oral Communications - Day 3

indexing

INDEXING
  • PubMed
  • Scopus
  • Web of Science
  • Google Scholar
  • OpenAlex
  • Scilit
  • DOAJ
  • Società Italiana di Reumatologia
  • Analytics

linkedin

Follow Reumatismo on

Vol. 78 No. 1 (2026)
The Italian Society for Rheumatology guidelines for the treatment of patients with rheumatoid arthritis and interstitial lung disease
Chiara Crotti et al.
10 November 2025
Vol. 78 No. 1 (2026)
From anatomy to therapy: the historical journey to cortisone
Ernesto Damiani et al.
19 November 2025
Vol. 78 No. 1 (2026)
Computed tomography of interstitial lung disease in systemic sclerosis: dataset and deep learning model for pulmonary lesion segmentation
Amir M. Vahdani et al.
25 February 2026
Vol. 78 No. 1 (2026)
Macrophage activation syndrome and rapidly progressive lung disease as life-threatening manifestations of anti-MDA5 antibody disease. A case report
Filippo Gozzi et al.
22 December 2025

Keywords

Reumatismo - The Italian Journal of Rheumatology

is the Official Journal of the Italian Society of Rheumatology (SIR). Founded in 1949. Published online by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.

pISSN: 0048-7449
eISSN: 2240-2683

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors
Themes by Openjournaltheme.com

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185    •    Privacy